首页> 外文期刊>Expert opinion on therapeutic targets >Targeting the angiotensin pathway in idiopathic pulmonary fibrosis.
【24h】

Targeting the angiotensin pathway in idiopathic pulmonary fibrosis.

机译:靶向特发性肺纤维化中的血管紧张素途径。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The angiotensin pathway is involved in the pathogenesis of many fibrotic diseases and in idiopathic pulmonary fibrosis an innate overexpression of angiotensin II, a potent TGF-beta1 inductor has been demonstrated. Angiotensin II therapeutic blockade could be therefore a promising antifibrotic approach. OBJECTIVE: Discussion of the results of a preclinical study assessing the antifibrotic efficacy of olmesartan and PD123319 in an experimental lung fibrosis. METHODS/RESULTS: This study demonstrated that in belomycin-induced pulmonary fibrosis both compounds had significant anti-inflammatory and antifibrotic activities. CONCLUSION: Targeting the angiotensin pathway with specific blocking agents could represent a promising antifibrotic treatment.
机译:背景:血管紧张素途径涉及许多纤维化疾病的发病机理,在特发性肺纤维化中血管紧张素II的先天过表达,已证明是一种有效的TGF-β1诱导剂。因此,血管紧张素II治疗性阻断可能是一种有希望的抗纤维化方法。目的:讨论一项临床前研究的结果,该研究评估奥美沙坦和PD123319在实验性肺纤维化中的抗纤维化功效。方法/结果:这项研究表明,在贝洛霉素诱导的肺纤维化中,两种化合物均具有显着的抗炎和抗纤维化活性。结论:以特异性阻断剂靶向血管紧张素途径可能代表一种有希望的抗纤维化治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号